Apoptotic death of hematopoietic tumor cells through potentiated and sustained adhesion to fibronectin via VLA-4. 2010

Yohei Saito, and Toshiyuki Owaki, and Takuya Matsunaga, and Mizue Saze, and Shogo Miura, and Mao Maeda, and Mayu Eguchi, and Rika Tanaka, and Junichi Taira, and Hiroaki Kodama, and Sumio Goto, and Yoshiroh Niitsu, and Hiroshi Terada, and Fumio Fukai
Department of Molecular Patho-Physiology, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda-Shi, Chiba 278-8510, Japan.

It has been postulated that inactivated beta1-integrins are involved in the disordered growth of hematopoietic tumor cells. We recently found that TNIIIA2, a peptide derived from tenascin-C, strongly activates beta1-integrins through binding with syndecan-4. We show here that Ramos Burkitt's lymphoma cells can survive and grow in suspension but undergo apoptosis when kept adhering to fibronectin by stimulation with TNIIIA2. Other integrin activators, Mg(2+) and TS2/16 (an integrin-activating antibody), were also capable of inducing apoptosis. The inactivation of ERK1/2 and Akt and the subsequent activation of Bad were involved in the apoptosis. The results using other hematopoietic tumor cell lines expressing different levels of fibronectin receptors (VLA-4 and VLA-5) showed that potentiated and sustained adhesion to fibronectin via VLA-4 causally induces apoptosis also in various types of hematopoietic tumor cells in addition to Ramos cells. Because TNIIIA2 requires syndecan-4 as a membrane receptor for activation of beta1-integrins, it induced apoptosis preferentially in hematopoietic tumor cells, which expressed both VLA-4 and syndecan-4 as membrane receptors mediating the effects of fibronectin and TNIIIA2, respectively. Therefore, normal peripheral blood cells, such as neutrophils, monocytes, and lymphocytes, which poorly expressed syndecan-4, were almost insusceptible to TNIIIA2-induced apoptosis. The TNIIIA2-related matricryptic site of TN-C could contribute, once exposed, to preventing prolonged survival of hematopoietic malignant progenitors through potentiated and sustained activation of VLA-4.

UI MeSH Term Description Entries
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D002051 Burkitt Lymphoma A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative. African Lymphoma,Burkitt Cell Leukemia,Burkitt Tumor,Lymphoma, Burkitt,Burkitt Leukemia,Burkitt's Leukemia,Burkitt's Lymphoma,Burkitt's Tumor,Leukemia, Lymphoblastic, Burkitt-Type,Leukemia, Lymphocytic, L3,Lymphocytic Leukemia, L3,Burkitts Leukemia,Burkitts Lymphoma,Burkitts Tumor,L3 Lymphocytic Leukemia,L3 Lymphocytic Leukemias,Leukemia, Burkitt,Leukemia, Burkitt Cell,Leukemia, Burkitt's,Leukemia, L3 Lymphocytic,Lymphoma, African,Lymphoma, Burkitt's,Tumor, Burkitt,Tumor, Burkitt's
D002448 Cell Adhesion Adherence of cells to surfaces or to other cells. Adhesion, Cell,Adhesions, Cell,Cell Adhesions
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D005353 Fibronectins Glycoproteins found on the surfaces of cells, particularly in fibrillar structures. The proteins are lost or reduced when these cells undergo viral or chemical transformation. They are highly susceptible to proteolysis and are substrates for activated blood coagulation factor VIII. The forms present in plasma are called cold-insoluble globulins. Cold-Insoluble Globulins,LETS Proteins,Fibronectin,Opsonic Glycoprotein,Opsonic alpha(2)SB Glycoprotein,alpha 2-Surface Binding Glycoprotein,Cold Insoluble Globulins,Globulins, Cold-Insoluble,Glycoprotein, Opsonic,Proteins, LETS,alpha 2 Surface Binding Glycoprotein
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015398 Signal Transduction The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway. Cell Signaling,Receptor-Mediated Signal Transduction,Signal Pathways,Receptor Mediated Signal Transduction,Signal Transduction Pathways,Signal Transduction Systems,Pathway, Signal,Pathway, Signal Transduction,Pathways, Signal,Pathways, Signal Transduction,Receptor-Mediated Signal Transductions,Signal Pathway,Signal Transduction Pathway,Signal Transduction System,Signal Transduction, Receptor-Mediated,Signal Transductions,Signal Transductions, Receptor-Mediated,System, Signal Transduction,Systems, Signal Transduction,Transduction, Signal,Transductions, Signal
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines

Related Publications

Yohei Saito, and Toshiyuki Owaki, and Takuya Matsunaga, and Mizue Saze, and Shogo Miura, and Mao Maeda, and Mayu Eguchi, and Rika Tanaka, and Junichi Taira, and Hiroaki Kodama, and Sumio Goto, and Yoshiroh Niitsu, and Hiroshi Terada, and Fumio Fukai
June 1994, Immunology,
Yohei Saito, and Toshiyuki Owaki, and Takuya Matsunaga, and Mizue Saze, and Shogo Miura, and Mao Maeda, and Mayu Eguchi, and Rika Tanaka, and Junichi Taira, and Hiroaki Kodama, and Sumio Goto, and Yoshiroh Niitsu, and Hiroshi Terada, and Fumio Fukai
July 2009, The Journal of biological chemistry,
Yohei Saito, and Toshiyuki Owaki, and Takuya Matsunaga, and Mizue Saze, and Shogo Miura, and Mao Maeda, and Mayu Eguchi, and Rika Tanaka, and Junichi Taira, and Hiroaki Kodama, and Sumio Goto, and Yoshiroh Niitsu, and Hiroshi Terada, and Fumio Fukai
January 1991, Journal of immunology (Baltimore, Md. : 1950),
Yohei Saito, and Toshiyuki Owaki, and Takuya Matsunaga, and Mizue Saze, and Shogo Miura, and Mao Maeda, and Mayu Eguchi, and Rika Tanaka, and Junichi Taira, and Hiroaki Kodama, and Sumio Goto, and Yoshiroh Niitsu, and Hiroshi Terada, and Fumio Fukai
September 2010, Journal of immunology (Baltimore, Md. : 1950),
Yohei Saito, and Toshiyuki Owaki, and Takuya Matsunaga, and Mizue Saze, and Shogo Miura, and Mao Maeda, and Mayu Eguchi, and Rika Tanaka, and Junichi Taira, and Hiroaki Kodama, and Sumio Goto, and Yoshiroh Niitsu, and Hiroshi Terada, and Fumio Fukai
July 1998, Cellular immunology,
Yohei Saito, and Toshiyuki Owaki, and Takuya Matsunaga, and Mizue Saze, and Shogo Miura, and Mao Maeda, and Mayu Eguchi, and Rika Tanaka, and Junichi Taira, and Hiroaki Kodama, and Sumio Goto, and Yoshiroh Niitsu, and Hiroshi Terada, and Fumio Fukai
December 1999, British journal of haematology,
Yohei Saito, and Toshiyuki Owaki, and Takuya Matsunaga, and Mizue Saze, and Shogo Miura, and Mao Maeda, and Mayu Eguchi, and Rika Tanaka, and Junichi Taira, and Hiroaki Kodama, and Sumio Goto, and Yoshiroh Niitsu, and Hiroshi Terada, and Fumio Fukai
March 2001, Experimental hematology,
Yohei Saito, and Toshiyuki Owaki, and Takuya Matsunaga, and Mizue Saze, and Shogo Miura, and Mao Maeda, and Mayu Eguchi, and Rika Tanaka, and Junichi Taira, and Hiroaki Kodama, and Sumio Goto, and Yoshiroh Niitsu, and Hiroshi Terada, and Fumio Fukai
August 1994, American journal of respiratory cell and molecular biology,
Yohei Saito, and Toshiyuki Owaki, and Takuya Matsunaga, and Mizue Saze, and Shogo Miura, and Mao Maeda, and Mayu Eguchi, and Rika Tanaka, and Junichi Taira, and Hiroaki Kodama, and Sumio Goto, and Yoshiroh Niitsu, and Hiroshi Terada, and Fumio Fukai
August 1997, Journal of immunology (Baltimore, Md. : 1950),
Yohei Saito, and Toshiyuki Owaki, and Takuya Matsunaga, and Mizue Saze, and Shogo Miura, and Mao Maeda, and Mayu Eguchi, and Rika Tanaka, and Junichi Taira, and Hiroaki Kodama, and Sumio Goto, and Yoshiroh Niitsu, and Hiroshi Terada, and Fumio Fukai
June 1992, Clinical and experimental immunology,
Copied contents to your clipboard!